key: cord-0742971-oek1yavk
authors: Pringle, Eric S.; Duguay, Brett A.; Bui-Marinos, Maxwell P.; Mulloy, Rory P.; Landreth, Shelby L.; Desireddy, Krishna Swaroop; Dolliver, Stacia M.; Ying, Shan; Caddell, Taylor; Slaine, Patrick D.; Bearne, Stephen L.; Falzarano, Darryl; Corcoran, Jennifer A.; Khaperskyy, Denys A.; McCormick, Craig
title: Thiopurines inhibit coronavirus Spike protein processing and incorporation into progeny virions
date: 2022-04-01
journal: bioRxiv
DOI: 10.1101/2022.03.10.483772
sha: 732c406f7670c0a6dfbfc0d71cb4693957272bda
doc_id: 742971
cord_uid: oek1yavk

There is an outstanding need for broadly acting antiviral drugs to combat emerging viral diseases. Here, we report that thiopurines inhibit the replication of the betacoronaviruses HCoV-OC43 and SARS-CoV-2, and to a lesser extent, the alphacoronavirus HCoV-229E. 6-Thioguanine (6-TG) disrupted early stages of infection, limiting synthesis of full-length and subgenomic HCoV RNAs. Furthermore, consistent with our previous report on the effects of thiopurines on influenza A virus glycoproteins, we observed that 6-TG inhibited accumulation of Spike glycoproteins from diverse HCoVs. Specifically, 6-TG treatment decreased the accumulation of Spike proteins and increased their electrophoretic mobility, consistent with Spike migration following the enzymatic removal of N-linked oligosaccharides with Peptide:N-glycosidase F (PNGaseF). SARS-CoV-2 virus-like particles (VLPs) harvested from 6-TG-treated cells were deficient in Spike. 6-TG treatment had a similar effect on lentiviruses pseudotyped with SARS-CoV-2 Spike; lentiviruses could be harvested from cell supernatants but were deficient in Spike and unable to infect human cells bearing ACE2 receptors. Together, these findings from complementary ectopic expression and infection models strongly indicate that defective Spike trafficking and processing is an outcome of 6-TG treatment. At low micromolar doses, the primary known mode of action of 6-TG is selective inhibition of the small GTPase Rac1. However, we observed that selective chemical inhibitors of the small GTPases Rac1, CDC42 and Rho had no effect on Spike processing and accumulation. The GTPase agonist ML099 countered the effects of 6-TG, suggesting that an unknown GTPase could be the relevant 6-TG-target protein involved in regulating Spike processing and accumulation. Overall, these findings provide important clues about the mechanism of action of a candidate antiviral that can broadly target HCoVs and suggest that small GTPases are promising targets for host-targeted antivirals. AUTHOR SUMMARY The COVID-19 pandemic has ignited efforts to repurpose existing drugs as safe and effective antivirals. Rather than directly inhibiting viral enzymes, host-targeted antivirals inhibit host cell processes to indirectly impede viral replication and/or stimulate antiviral responses. Here, we describe a new antiviral mechanism of action for the FDA-approved thiopurine 6-thioguanine. We demonstrate that this thiopurine is a pro-drug that must be metabolized by host enzymes to gain antiviral activity. We show that it can inhibit the replication of several human coronaviruses, including SARS-CoV-2, at least in part by interfering with the processing and accumulation of Spike glycoproteins, thereby impeding assembly of infectious progeny viruses. We provide evidence implicating host cell GTPase enzymes in the antiviral mechanism of action.

Coronaviruses (CoVs) are enveloped viruses with positive-sense, single-stranded RNA 67 ((+)ssRNA) genomes. Seven human CoVs (HCoVs) are divided into two genera, the 68 alphacoronaviruses (HCoV-NL63 and HCoV-229E) and betacoronaviruses (HCoV-OC43, HCoV-69 HKU1, MERS-CoV, SARS-CoV and SARS-CoV-2). Following entry into host cells, the 70 (+)ssRNA CoV genome is immediately translated into polyproteins that are cleaved by viral 71 cysteine proteases into 16 non-structural proteins (NSPs). These NSPs include the transmembrane 72 nsp3-nsp4-nsp6 complex that generates a complex endoplasmic reticulum (ER)-derived 73 reticulovesicular network that includes replication organelles known as double-membrane vesicles 74 (DMVs) (1-8). In DMVs, the nsp3-nsp4-nsp6 complex provides a physical anchor for the viral 75

replicase-transcriptase complex (RTC) that replicates the large viral genome and synthesizes 76 subgenomic mRNAs (9, 10). These viral RNAs traverse a crown-shaped pore to exit the DMV (8). 77

In the cytoplasm, viral mRNAs are translated into structural proteins; Nucleocapsid (N) is 78 synthesized via free ribosomes in the cytoplasm, whereas mRNAs encoding envelope proteins are 79 translated and processed in the ER and accumulate in the ER-Golgi-intermediate compartment 80

(ERGIC). HCoV assembly takes place when full-length viral genomic RNA coated with N buds 81 into the ERGIC to acquire the viral envelope and associated envelope proteins (11-13). These 82 progeny viruses traverse the Golgi apparatus and trans-Golgi network (TGN), where envelope 83 lysates harvested from SARS-CoV-2-infected Calu-3 cells at 48 h post-infection showed a sharp 237 decrease in all four structural proteins following 6-TG treatment (Fig. 3A) , consistent with a sub-238 micromolar EC50 discussed above (Fig. 1B) . Treatment of SARS-CoV-2-infected Huh-7.5 cells 239 with 10 µM 6-TG also reduced the accumulation of viral structural proteins, which was especially 240 evident for Spike (Fig. 3B) . These findings led us to further investigate the effects of 6-TG on 241 SARS-CoV-2 structural proteins. Transfection of 293T cells with plasmids encoding each SARS-242

CoV-2 structural protein revealed that 6-TG had no effect on E or N accumulation, whereas Spike 243 processing was noticeably inhibited (Fig. 3C) . We also observed that 6-TG treatment caused a loss 244 of a slow-migrating species of M (Fig. 3C) , which likely represented the glycosylated form of the 245 protein that has been previously reported for other HCoVs (50). Thus, it appears that amongst the 246 SARS-CoV-2 structural proteins, only the glycosylated Spike and M proteins are altered by 6-TG 247 treatment when expressed independently in 293T cells. 248

To further explore the effects of 6-TG on Spike, we ectopically expressed Spike, then 249 treated the cells with a range of sub-cytotoxic 6-TG concentrations before harvesting lysates and 250 processing for immunoblotting (Figs. 3D, 3E) . Spike appeared as two bands when immunoblots 251 are probed with an anti-S1 receptor binding domain (RBD) antibody, a high-molecular weight 252 (MW) precursor S0 band (~203 kDa) and a lower molecular weight band representing the protease-253 cleaved S1 attachment protein (~96 kDa). Increasing concentrations of 6-TG once again led to the 254 accumulation of a prominent single band at an unexpected MW (~137 kDa) (Fig. 3D) . Because 6-255 TG treatment caused Spike to migrate faster during SDS-PAGE than expected, we hypothesized 256 that the lower MW species observed only in 6-TG treated samples could arise from a glycosylation 257 defect. We treated lysates from Spike-expressing 293T cells with Peptide-N-Glycosidase F 258 (PNGase F), an amidase that cleaves the bond between N-acetylglucosamine (GlcNAc) and 259 asparagine, effectively removing all N-linked glycans from the polypeptide chain (unless the core 260

GlcNAc is modified by a-1,3-fucose) (51) . PNGase F treatment caused Spike from the DMSO-261 treated cells to migrate similarly to Spike from 6-TG-treated cells (Fig. 3F) . We confirmed the 262 identity of the high MW Spike band as the uncleaved S0 precursor protein by generating and 263 testing a mutant Spike protein in which the basic residues in the furin cleavage site joining S1 and 264 S2 were substituted with alanines, yielding a protease cleavage-resistant Spike protein. Cells 265 transfected with this S0 construct and treated with 6-TG prior to lysis revealed that the S0 construct 266 was also sensitive to PNGaseF treatment; the 6-TG/PNGaseF-treated S0 migrated similarly to 6-267 TG/PNGaseF-treated WT Spike by SDS-PAGE. Several studies have mapped O-linked glycans 268 on SARS-CoV-2 Spike (52-54) and these modifications appear to follow the "O-follow-N rule" 269 whereby N-glycosylation is followed by O-glycosylation on nearby residues (52). Thus, the 270 apparent differences in molecular weight between vehicle/PNGaseF-treated Spike and 6-271 TG/PNGaseF-treated Spike could stem from residual O-linked glycans on Spike that are absent in 272 the 6-TG-treated proteins. These findings were corroborated using carboxy-terminal FLAG-tagged 273

Spike proteins from SARS-CoV-2 and MERS-CoV that also displayed a fast-migrating, under-274 glycosylated S0 species and loss of the S2 subunit following 6-TG treatment (Fig. 3G) . Taken 275 together, these results suggest that 6-TG inhibits normal glycosylation and processing of Spike. 276 A failure of Spike to migrate efficiently from the ER to the Golgi could inhibit glycan 277 maturation and cleavage by furin. In our previous work, we observed that 6-TG treatment did not 278 reduce levels of Class I HLA proteins at the cell surface (34), which we interpreted as evidence 279 that 6-TG did not globally affect processing and secretion of host cell glycoproteins. Here, we 280 tested the role of 6-TG on the secretory pathway by using a Gaussia luciferase assay in which the 281 enzyme depends on a native secretion signal to be secreted (55). As a control we used the Arf1-282 inhibitor brefeldin A (BFA) which potently inhibits protein trafficking from the ER to the Golgi 283 (56, 57). BFA is toxic to cells at micromolar doses, but we could still detect secretory pathway 284 inhibition at 250 nM for 20 h without overt cytotoxicity (Figs. S2A, S2B) . A short-term, 6 h 285 treatment with 6-TG (10 µM) had little effect on Gaussia luciferase secretion, whereas treatment 286 with BFA (10 µM) greatly decreased secretion. We tested a longer 20 h treatment of 6-TG where 287 we co-transfected Firefly luciferase (Luc2) with Gaussia luciferase to help control for the 288 inhibitory effects of 6-TG on 293T cell proliferation. This extended 6-TG treatment caused a slight 289 loss of detectable Gaussia luciferase activity in the cell supernatant, but once again low-dose 290 treatment of BFA greatly inhibited secretion and increased intracellular retention of Gaussia 291 luciferase (Fig. S2C) . These experiments strongly corroborated our prior observations that 6-TG 292 treatment does not globally disrupt the secretory pathway. Because of our previous observations 293 of 6-TG-mediated defects in Spike glycosylation, processing and trafficking, we decided to test 294 whether low-dose, long-term treatment with BFA would be sufficient to recapitulate the effects of 295 6-TG treatment on Spike. However, unlike 6-TG, the secretion inhibitor BFA did not cause any 296 changes in Spike accumulation or processing, as indicated by identical electrophoretic mobility of 297 Spike on immunoblots compared to vehicle control (Fig. S2D) . 298

To directly monitor Spike protein secretion, we used flow cytometry and surface staining 299 of unpermeablized 293T cells transfected with Spike. We co-transfected cells with an EGFP 300 plasmid and gated on EGFP+ cells to measure changes in Spike accumulation. 6-TG reduced 301 surface expression of Spike by ~50% resulting in fewer Spike-positive cells and reduced mean 302 fluorescence intensity. In these experiments, we also tested a Spike protein in which the 19 C-303 terminal residues were removed (Spike-Δ19); this widely-used strategy removes an ER-retrieval 304 signal and enhances incorporation of Spike into lentivirus particles (58-60). We found a similar 305 ~50% reduction in trafficking and surface expression of Spike-Δ19 (Fig. S2E) transfected into cells, 6-TG treatment not only altered the accumulation and processing of Spike, 314 but also dramatically reduced accumulation of E and M proteins (Fig. 4A) . Cell supernatants were 315 collected, filtered and pelleted in a sucrose cushion to isolate VLPs, which were then characterized 316 by immunoblotting. We observed a dramatic reduction in VLP production from 6-TG-treated 293T 317 cells, and these residual VLPs completely lacked Spike (Fig. 4B) . These findings indicate that 6-318 TG not only prevents Spike processing and accumulation, but also its incorporation into VLPs. 319

We then co-transfected cells again with only three of the four Spike, E, M, and N encoding 320 plasmids to better understand mechanisms of defective assembly. Our main conclusions are: 1) 6-321 TG treatment of cells expressing all structural proteins causes a strong Spike-dependent decrease 322 in E expression, 2) in the absence of M the 6-TG-mediated Spike glycosylation defect is more 323 pronounced, and 3) N is required for accumulation of E (Fig 4C) . To determine if Spike from 6-324 TG treated cells was still functional, we employed a lentivirus pseudotyping method using Spike-325 Δ19, which is widely used to measure neutralizing antibody titers to SARS-CoV-2 (58, 62, 63). 326

We performed immunoblots on pseudotyped viruses (PVs) recovered from three independent 327 preparations that we purified by ultracentrifugation through a 20% sucrose cushion. Unlike our 328 previous immunoblots of ectopically expressed Spike from transfected cells, we observed that 329 most of the Spike proteins incorporated into the PVs were fully cleaved into the prominent S1 330 band (Fig. 4D) . However, 6-TG treatment led to a dramatic loss of Spike S0 and S1 species from 331 the purified PVs, compared to the smaller decrease observed for HIV p24 levels in PV cores. We 332 quantified PV yield from these cells by amplifying lentiviral genomes via RT-qPCR from filtered, 333 unconcentrated cell supernatants. 6-TG treatment did not significantly reduce the quantity of 334 capsid-protected genomes released from cells compared to vehicle control (Fig. 4E) . To determine 335 the effects of 6-TG on PV infectivity, we used purified PVs to infect HEK293A cells that stably 336 express the ACE2 receptor and measured luciferase production in the recipient cells as a measure 337 of successful lentiviral infection. Consistent with deficient Spike incorporation into PVs, we 338 observed that 6-TG treatment reduced PV infectivity by over 50-fold compared to PVs derived 339 from vehicle-treated cells (Fig. 4F) . By contrast, PVs derived from vehicle control-and 6-TG-340 treated cells were equally competent to infect ACE2-deficient HEK293A cells at low levels. This 341 suggests that 6-TG treatment not only inhibits Spike glycosylation and processing, but it also 342 inhibits Spike trafficking and incorporation into lentiviral particles. We next investigated whether 343 these 6-TG-mediated assembly defects altered the morphology of HCoV particles. We 344 concentrated supernatant from HCoV-OC43 infected 293A cells by ultracentrifugation and imaged 345 virions by transmission electron microscopy using negative staining. We observed fewer viral 346 particles in the 6-TG treated samples, and while these particles were of similar size, we noted fewer 347 particles with clearly discernible Spikes (Fig. 4G) . Taken together, the strong effects of 6-TG on 348 Spike in transiently transfected cells, heterologous lentivirus production and infection, and 349 authentic HCoV infections, provide evidence for an additional antiviral mode of action for 6-TG 350 beyond PLpro/nsp3 inhibition or defects in viral RNA synthesis. 351 352 6-Thioguanine must be processed by HPRT1 to inhibit Spike processing and coronavirus 353 replication. We observed comparable antiviral activities of 6-TG and its ribose-conjugated 354 analogue 6-TGo throughout these studies. Metabolism of 6-TG is initiated by the purine 355 scavenging enzyme hypoxanthine phosphoribosyltransferase 1 (HPRT1) to yield 6-thioguanosine 356 5'-monophosphate (6-TGMP) (Fig. 5A) . 6-TGMP can then be converted to 6-thioguanosine 5'-357 triphosphate (6-TGTP), the active form of the molecule that has been shown to form a covalent 358 bond with a reactive cysteine in the p-loop of Rac1; subsequent hydrolysis of Rac1-6-TGTP to a 359 diphosphate form renders the GTPase inactive (37). Considering this information, we next sought 360 13 to determine whether conversion of 6-TG to a ribonucleoside was required for its antiviral activity. 361

First, we synthesized N9-methyl 6-thioguanine (6-TG-Me), which prevents conjugation to a ribose 362 sugar due to the methyl group at N9 of the purine ring and is predicted to be resistant to conversion 363 into 6-TGMP (Fig. 5A) . 6-TG-Me displayed low cytotoxicity and no antiviral activity against 364

HCoV-OC43 across a broad range of concentrations (Fig. 5B) . Likewise, 6-TG-Me had no effect 365 on SARS-CoV-2 Spike processing across a range of concentrations between 5 µM and 20 µM 366 (Fig. 5C ). To corroborate this finding, we used RNA interference to silence expression of HPRT1 367 in 293T cells prior to infection with HCoV-OC43 and treatment with 6-TG or vehicle control. RT-368 qPCR confirmed effective silencing of HPRT1 (Fig. 5D) , which had no effect on HCoV-OC43 369 infection in vehicle control-treated cells (Fig. 5E ). By contrast, HPRT1 silencing significantly 370 restored viral replication in the presence of 6-TG, although replication did not return to the levels 371 in control cells. Together, these findings indicate that 6-TG is a pro-drug that must be metabolized 372 by HPRT1 to convert it to an active form. 373 374 6-Thioguanine inhibits Spike maturation by inhibiting an unidentified cellular GTPase. 6-375 TG inhibits several different GTPases including Rac1, RhoA, and Cdc42 (37, 43, 44). This mode 376 of action was previously shown to inhibit rotavirus replication at sub-micromolar concentrations 377 (64) . Here, we sought to determine if any of the known targets of 6-TG were responsible for defects 378

in Spike maturation. We tested known inhibitors of Rac1 (Rac1 Inhibitor V), RhoA (Rhosin), and 379 Cdc42 (CASIN) for cytotoxic effects in 293T cells after 24 h incubation using an alamarBlue assay 380 to identify optimal sub-cytotoxic doses for further testing (Figs. 6A, 6B) . We also tested a GTPase 381 agonist ML099 that can potently activate Rac1, RhoA, and Cdc42, among other GTPases (65). 382

None of the three GTPase inhibitors had any effect on Spike processing or accumulation (Fig. 6C) . 383 Because many additional GTPases have redox-sensitive cysteine residues that could interact with 384 6-TG, we reasoned that 6-TG could affect viral glycoproteins through an as-yet-unidentified 385

GTPase. In support of this notion, we observed that the broadly acting small GTPase agonist 386 ML099 maintained normal Spike processing in the presence of 6-TG (Fig. 6D) . Pre-treating the 387 cells with ML099 before addition of 6-TG further enhanced this effect (Fig. 6E) . We attempted to 388 rescue HCoV-OC43 titer in both HCT-8 and 293A infection models but instead found that ML099 389 was itself acting as an antiviral agent (Fig. 6F) . While this was worth testing, this result was 390 unsurprising as viral infection likely requires specific or unperturbed GTPase function, including 391 frequent cycling between GTP-and GDP-bound forms. Overall, these data suggest that 6-TG 392 inhibits Spike maturation by inhibiting an unidentified cellular GTPase. 393

The reliance of viruses on the host cell biosynthetic and secretory apparatus, combined with the 396 existence of varied and potent host antiviral mechanisms, makes host targeted antivirals (HTAs) 397 useful additions to our armamentarium of direct-acting antivirals (DAAs). By targeting these host 398 cell processes, HTAs may not be so easily subverted by the rapid viral evolution that frequently 399 undermines DAAs. We recently reported that the thiopurines 6-TG and 6-TGo inhibit influenza A 400 virus (IAV) by selectively disrupting the normal processing and accumulation of HA and NA 401 glycoproteins (34). We hypothesized that other enveloped viruses that rapidly produce a burst of 402 viral glycoproteins would also be susceptible to these thiopurines. Here, we report that the 403 thioguanine 6-TG disrupts the normal processing and accumulation of CoV Spike glycoproteins 404 and inhibits the release of infectious progeny. This drug-induced Spike processing defect disrupts 405 the incorporation of SARS-CoV-2 Spike into VLPs or pseudotyped lentiviruses, which 406 subsequently prevents infection of susceptible, ACE2-expressing cells. Thiopurines inhibit the 407 small GTPase Rac1 by forming a covalent bond with a redox-sensitive cysteine, preventing further 408 guanine nucleotide exchange. However, we show that selective chemical inhibitors of Rac1 or 409 related small GTPases CDC42 and Rho had no effect on Spike processing and accumulation, 410 whereas a broad GTPase agonist was able to counter the effects of 6-TG. This indicates that there 411 are additional, unknown GTPase targets of 6-TG and that these are required for normal Spike 412 processing and accumulation. Together, these findings suggest that functional small GTPases are 413 essential for virus replication and that further development of GTPase inhibitors as host-directed 414 antivirals is warranted. 415

We were intrigued by how 6-TG and 6-TGo strongly inhibited processing and 416 accumulation of IAV and CoV glycoproteins. However, we also observed that these thiopurines 417 had little effect on global host protein synthesis and secretion. Together, these observations suggest 418 that viral glycoproteins may have properties that make them especially sensitive to these drugs. 419

Certainly, viral glycoproteins must adhere to temporal or physical constraints that most host 420 glycoproteins do not. All glycoproteins are synthesized, folded and post-translationally modified 421 in the ER. However, viral glycoproteins can impose an acute burden on the ER when they are 422 rapidly synthesized in large numbers in a relatively brief time frame. This burden may differ in 423 severity depending on the extent of shutoff of host gene expression, as viruses with efficient host 424 shutoff mechanisms would deplete host glycoproteins and facilitate viral utilization of the cellular 425 biosynthetic and secretory apparatus. Viral envelope proteins are often more heavily glycosylated 426 than their host counterparts, which can shield them from antibody recognition. Because N-427 glycosylation is a dynamic process involving glycan trimming and maturation, viral infection may 428 impose specific burdens on these components of the ER quality control machinery. This may result 429 in delayed trafficking of glycoproteins through the secretory pathway, leading to their degradation. 430

Finally, it should be noted that viral glycoproteins are often assembled into large homo-and hetero-431 oligomeric complexes that must traffic to sites of assembly. Together, these aspects of viral 432 glycoprotein biology place additional burdens on the ER and the associated machinery that governs 433 glycoprotein folding, modification and trafficking. 434

Because cellular GTPases play important roles in viral glycoprotein biogenesis and 435 trafficking, they may be good targets for host-directed antivirals. Viral assembly occurs at distinct 436 sites like the plasma membrane (influenza A viruses) or the ERGIC (coronaviruses). Small 437 molecules that disrupt efficient viral glycoprotein processing, oligomerization and trafficking 438 could have the effect of 'misplacing' these important viral components and inhibiting essential 439 steps in viral assembly and egress. We speculate that 6-TG and 6-TGo inhibit GTPases involved 440

in key steps of viral glycoprotein synthesis, processing and trafficking, diverting them from their 441 roles in viral assembly and consigning them to degradation via cellular catabolic processes. While 442 these drugs are well-tolerated in humans, we believe that more can be gained by identifying new 443 target GTPase(s) and further elucidating the antiviral mechanism of action to inform the 444 development of novel chemical entities with superior properties. Table 1 . Primer sequences for RT-qPCR analysis 708 Laemmli buffer. Samples from two independent lentivirus preparations were probed by western blotting as indicated. (C) 293T cells were transfected with S, E, M, and N in a 1:2:2:1 ratio, substituting one of the structural proteins for EV as indicated, treated with 6-TG or DMSO then processed as in (A). (D) SARS-CoV-2 Spike pseudotyped, luciferase-expressing lentivirus particles were concentrated by ultracentrifugation through a 20% sucrose cushion, resuspended in PBS, then harvested with an equal volume of 2x Laemmli buffer. Samples from three independent lentivirus preparations were probed by western blotting as indicated. (E) Genomes from three independent lentivirus preparations were quantified by RT-qPCR (n=3, statistical significance was determined by paired t-test; ns, non-significant). (F) 293A cells stably expressing ACE2 or empty vector control were transduced with lentivirus from three independent preparations. After 24 h, lysates were harvested and measured for luciferase activity (n=3, statistical significance was determined by two-way ANOVA; *, p<0.05; ns, non-significant). (G) 293A cells were infected HCoV-OC43 at an MOI of 0.1 =, then treated with 6-TG or DMSO. Supernatants were concentrated as in (C), before virions were fixed and imaged by TEM with negative staining. were infected with an MOI of~0.1 then treated with 10 µM 6-TG or DMSO vehicle control. After 24 h, the supernatants was harvested and stored at -80°C until titering on BHK-21 (n=3 ± SEM, statistical significance was determined by one-way ANOVA; *, p<0.05; **, p<0.01; ns, non-significant). LoD = Limit of Detection for virus titer. Cells were treated with 10 µg/mL of puromycin for 10 min prior to harvest 24 h after infection. Lysates were probed by western blot as indicated. (C) Total puromycin intensity from (E) was quantified relative to total protein load and are graphed normalized to the mock-infected, DMSO-treated cells (n=3 ± SEM, statistical significance was determined by paired t-test compared to mock-infected, DMSO-treated cells; *, p<0.05; **, p<0.01; ***, p<0.001; ns, non-significant). 

Enzymatic approaches for studying the 1010 structure, synthesis, and processing of glycoproteins

O-glycosylation pattern of the SARS-CoV-2 spike protein reveals an "O-Follow-N" 1013 rule

N-and O-Glycosylation of the SARS-CoV-2 1015

Deducing the N-and O-1017 glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2

optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo

Inhibition by brefeldin A of a Golgi membrane enzyme that 1023 catalyses exchange of guanine nucleotide bound to ARF

Brefeldin A inhibits Golgi membrane-1025 catalysed exchange of guanine nucleotide onto ARF protein

Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for 1029

pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing 1032 antibodies against SARS-CoV-2

Characterization of spike glycoprotein of 1035

SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat

Incorporation of spike and membrane glycoproteins into 1038 coronavirus virions

Establishment and validation of a 1041 pseudovirus neutralization assay for SARS-CoV-2

Measuring SARS-CoV-2 neutralizing antibody activity 1046 using pseudotyped and chimeric viruses

6-Thioguanine inhibits rotavirus replication through 1049 suppression of Rac1 GDP/GTP cycling

Activation of Rho Family GTPases by Small Molecules

Highly permissive cell lines for subgenomic and 1056 genomic hepatitis C virus RNA replication

KSHV activates unfolded protein response 1058 sensors but suppresses downstream transcriptional responses to support lytic replication

Two Detailed Plaque Assay Protocols 1061 for the Quantification of Infectious SARS-CoV-2

Direct Lysis RT-qPCR of SARS-CoV-2 in Cell Culture Supernatant Allows for Fast 1064 and Accurate Quantification

Cryo-EM structure of the 2019-nCoV spike in the prefusion 1067 conformation

Immunogenicity and structures of 1071 a rationally designed prefusion MERS-CoV spike antigen

Stabilized coronavirus spikes are resistant to 1075 conformational changes induced by receptor recognition or proteolysis

Photodynamic Inactivation of Human Coronaviruses

. 6-TG inhibits multiple essential steps in virus replication and assembly. 6-TG inhibits nsp3, delaying formation of replication compartments and reducing accumulation of viral RNA. 6-TG also inhibits normal glycosylation of Spike, which fails to be properly packaged in egressing virions. As a result, the total number of virions released from infected cells is reduced and those that are released have fewer Spikes on their surface.